Literature DB >> 11133872

Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice.

S E Brooks1, X Gu, S Samuel, D M Marcus, M Bartoli, P L Huang, R B Caldwell.   

Abstract

PURPOSE: Exposure of premature human infants to hyperoxia results in the obliteration of developing retina capillaries, leading to a vision-threatening retinopathy termed retinopathy of prematurity (ROP). The authors hypothesized that this process may be mediated in part by endothelial nitric oxide (NO)-derived oxidants such as peroxynitrite and tested this hypothesis in a mouse model of ROP.
METHODS: Normal mice, mice treated with the nitric oxide synthase (NOS) inhibitor N:(G)-nitro-L-arginine (L-NNA), and knockout mice carrying a homozygous targeted disruption of the gene for endothelial NOS (eNOS) were studied in an experimental model of ROP. Retinas were compared for extent of capillary obliteration in hyperoxia, vascular endothelial growth factor (VEGF) expression, nitrotyrosine formation, and vitreous neovascularization.
RESULTS: Oxygen-induced retinal vaso-obliteration was significantly reduced by L-NNA treatment (43% decrease from controls). The eNOS-deficient mice showed a similar reduction in vaso-obliteration (46% decrease from controls), and vitreous neovascularization was also substantially reduced (threefold decrease). Retinal nitrotyrosine formation, a measure of in situ peroxynitrite modification of proteins, was significantly elevated in normal mice during hyperoxia, in a spatial and temporal pattern consistent with a role in oxygen-induced vaso-obliteration. This was not seen in eNOS-deficient mice. VEGF expression was similar in both groups of mice, although suppression in hyperoxia was slightly blunted in eNOS-deficient mice.
CONCLUSIONS: These data suggest a role for NO and peroxynitrite in the pathogenesis of ROP. Therapies aimed at modulation of eNOS activity may have therapeutic potential for preventing ROP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11133872

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  53 in total

1.  More weapons in the arsenal against ischemic retinopathy.

Authors:  E Keshet
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

2.  Retinal features predictive of progressive stage 4 retinopathy of prematurity.

Authors:  M Elizabeth Hartnett; Janet R McColm
Journal:  Retina       Date:  2004-04       Impact factor: 4.256

3.  The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model.

Authors:  Grace Byfield; Steve Budd; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-05       Impact factor: 4.799

Review 4.  The role of genetic polymorphisms in antioxidant enzymes and potential antioxidant therapies in neonatal lung disease.

Authors:  Carlo Dani; Chiara Poggi
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 5.  Arginase: an old enzyme with new tricks.

Authors:  Ruth B Caldwell; Haroldo A Toque; S Priya Narayanan; R William Caldwell
Journal:  Trends Pharmacol Sci       Date:  2015-04-27       Impact factor: 14.819

6.  Endothelial nitric oxide synthase gene promoter polymorphism (T-786C) may be associated with advanced retinopathy of prematurity.

Authors:  Barkur S Shastry
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-28       Impact factor: 3.117

7.  Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina.

Authors:  Athanasia Skoura; Teresa Sanchez; Kevin Claffey; Suzanne M Mandala; Richard L Proia; Timothy Hla
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Attenuation of retinal vascular development and neovascularization in PECAM-1-deficient mice.

Authors:  Terri A Dimaio; Shoujian Wang; Qiong Huang; Elizabeth A Scheef; Christine M Sorenson; Nader Sheibani
Journal:  Dev Biol       Date:  2008-01-22       Impact factor: 3.582

9.  Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate.

Authors:  Koji M Nishiguchi; Keiko Kataoka; Shu Kachi; Keiichi Komeima; Hiroko Terasaki
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

Review 10.  Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy.

Authors:  Elsa Kermorvant-Duchemin; Przemyslaw Sapieha; Mirna Sirinyan; Martin Beauchamp; Daniella Checchin; Pierre Hardy; Florian Sennlaub; Pierre Lachapelle; Sylvain Chemtob
Journal:  Doc Ophthalmol       Date:  2009-10-31       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.